Biotechnology

What Are Genetic Mutations?

A genetic mutation, or variant, is a change in the DNA sequence. Some are inherited and present in every cell. Others arise during life in particular cells, as in cancer. Most have no effect, but some cause disease or change how a person responds to drugs.

Key points

  • A mutation, now usually called a variant, is a change in the DNA sequence compared with a reference sequence.
  • Germline variants are inherited and present in virtually every cell. Somatic variants arise during life in particular cells and are not passed to children.
  • Variants range from a single DNA letter to the gain or loss of large segments of chromosomes.
  • Clinical laboratories classify variants on a five-tier scale from pathogenic to benign, following guidelines from the American College of Medical Genetics and Genomics.
  • Many targeted cancer drugs are designed against specific somatic mutations, and some genetic variants are protective, revealing promising drug targets.

Your DNA is a sequence of about 3 billion chemical letters. A genetic mutation is a change in that sequence. The word "mutation" can sound alarming, but changes in DNA are common, and most of them have no noticeable effect. Some, however, cause disease, protect against it, or change how a person responds to medicines. That makes them central to modern drug development.

Mutation or variant?

Scientists and clinicians increasingly use the word variant rather than mutation. A variant is simply a difference from a reference DNA sequence. The neutral term avoids implying that every change is harmful, since many variants are harmless differences between healthy people. This article uses both terms.

Inherited versus acquired

The most important distinction is when a variant arose. MedlinePlus Genetics, from the National Library of Medicine, describes two categories:

Type Also called Where it is found Passed to children?
Inherited Germline, hereditary In the egg or sperm, and so in virtually every cell of the body Yes
Acquired Somatic Only in the cells descended from the cell where it arose No

Somatic variants accumulate throughout life, for example from errors when cells divide or damage from ultraviolet light or tobacco smoke. Cancer is fundamentally a disease of acquired variants: tumors develop when cells accumulate changes that let them grow uncontrollably.

Types of variants

Variant type What changes Possible effect
Substitution (point variant) One DNA letter is replaced by another May change one amino acid in a protein, stop the protein early, or have no effect
Insertion Extra DNA letters are added Can shift how the gene is read, disrupting the protein
Deletion DNA letters are removed Same as insertion; large deletions can remove whole genes
Duplication A stretch of DNA is copied Extra copies of a gene can increase its activity
Copy number variant Large segments are gained or lost Changes how much of a gene's product the cell makes
Chromosomal rearrangement Pieces of chromosomes break and rejoin Can fuse two genes into a new, abnormal one

How variants affect proteins

Genes provide instructions for making proteins, and a variant can change the protein in several ways:

  • Loss of function: the protein no longer works, or is not made at all.
  • Gain of function: the protein becomes overactive or acquires a new, harmful activity.
  • No effect: many variants change nothing important, for example because they fall outside the parts of a gene that matter or do not change the resulting amino acid.

The distinction matters for drug design. A disease caused by an overactive protein can often be treated with a drug that blocks it. A disease caused by a missing protein is harder: the protein must be replaced, or the gene repaired, for example with gene therapy or CRISPR gene editing.

How laboratories classify variants

When a genetic test finds a variant, a clinical laboratory must decide what it means. Guidelines published in 2015 by the American College of Medical Genetics and Genomics and the Association for Molecular Pathology established a five-tier scale:

  1. Pathogenic
  2. Likely pathogenic
  3. Uncertain significance
  4. Likely benign
  5. Benign

Classification weighs evidence such as how common the variant is in the general population, whether it tracks with disease in families, what laboratory experiments show about its effect, and what computer predictions suggest. A variant of uncertain significance is exactly that: there is not yet enough evidence to say whether it matters. The National Center for Biotechnology Information's public ClinVar database collects laboratories' interpretations of variants.

Variants and drug development

Targeting the mutation directly

Some of the most successful targeted drugs act on the abnormal protein produced by a specific acquired variant. Chronic myeloid leukemia is driven by a chromosomal rearrangement that fuses two genes and creates an overactive enzyme, BCR-ABL. Imatinib, which blocks that enzyme, produced complete hematologic responses in 53 of 54 patients at effective doses in an early trial reported in 2001. Many cancer drugs since then have been designed around a specific tumor mutation, with a test used to find patients whose tumors carry it. See What Is Precision Medicine?

Learning from protective variants

Some loss-of-function variants are protective. In 2006, researchers reported that people with variants disabling the PCSK9 gene had substantially lower LDL cholesterol and lower rates of coronary heart disease. That pointed to blocking PCSK9 as a treatment strategy, and drugs that do so were later approved. Protective variants are among the most valuable clues in drug discovery, because they show what happens when a target is switched off for a lifetime.

Variants that change drug response

Variants in genes for drug-metabolizing enzymes or immune proteins can make a drug less effective or more dangerous for some people. This is the field of pharmacogenomics. The FDA lists drugs whose labels include genetic information of this kind.

What a mutation in the news usually means

When a company describes a drug as "targeting KRAS mutations" or "for patients with a BRCA variant," it is describing a biomarker-defined population. That has three practical implications:

  • only patients whose tests show the variant are eligible,
  • a companion test may need regulatory approval alongside the drug, and
  • historically, biomarker-selected programs have had higher success rates than unselected ones.

Sources

  1. MedlinePlus Genetics (National Library of Medicine). What is a gene variant and how do variants occur?Regulator
  2. Richards S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genetics in Medicine. 2015;17(5):405–424.Peer-reviewed
  3. National Center for Biotechnology Information. ClinVar.Registry
  4. Druker BJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. New England Journal of Medicine. 2001;344(14):1031–1037.Peer-reviewed
  5. Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. New England Journal of Medicine. 2006;354(12):1264–1272.Peer-reviewed

This article is for education. It is not medical advice and not investment advice. Figures are drawn from the sources above and describe historical averages, not the prospects of any particular drug. See our editorial standards and disclaimer.